The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
ResMed Q1 EPS $1.51 Beats $1.36 Estimate, Sales $904.00M Beat $866.33M Estimate
ResMed (NYSE:RMD) reported quarterly earnings of $1.51 per share which beat the analyst consensus estimate of $1.36 by 11.03 percent. This is a 18.9 percent increase over earnings of $1.27 per share from the same period
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For October 28, 2021
Companies Reporting Before The Bell
• LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million.
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength.
The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 9)
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi’s Pemphigus Trial Disappointment, Humanigen’s COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 8)
The Daily Biotech Pulse: MacroGenics’ Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA’s FDA Nod
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 7)
Chief Administrative Officer Of Resmed Makes $434.44 Thousand Sell
David Pendarvis, Chief Administrative Officer at Resmed (NYSE:RMD), made a large insider sell on September 3, according to a new SEC filing.
President Of Resmed Makes $689.53 Thousand Sell
James Hollingshead, President of Resmed (NYSE:RMD), made a large insider sell on September 1, according to a new SEC